Skip to content
Bored Studies
RecruitingPhase 2/Phase 3

Redefine Study: A Study Evaluating the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder

COMPASS Pathways · NCT07570654

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18+ · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Phase 2, Phase 3
Target enrollment
300
US sites recruiting
9
Study start
September 2026
Record last updated
October 23, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

The Redefine Study (COMP202) is testing COMP360 to see if it may reduce post-traumatic stress disorder (PTSD) symptoms when administered alongside monitoring and support from a trained study team. COMP360 is a lab-made form of the naturally occurring chemical compound psilocybin.

Being studied: COMP360 psilocybin

Conditions: PTSD - Post Traumatic Stress Disorder; PTSD; PTSD Symptoms; PTSD, Post Traumatic Stress Disorder

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • 18 years or older
  • Diagnosed with PTSD at least 6 months ago

Exclusion Criteria

  • Diagnosed with certain psychiatric conditions such as bipolar disorder, schizophrenia, OCD, anorexia, or other conditions

Recruiting US locations

Study contacts (from the official record)

  • www.redefineptsdstudy.com Redefine Study Call Center · 202-459-9258 · TheRedefineStudy@compasspathways.com
All mental health studies in Arizona →
Redefine Study: A Study Evaluating the Efficacy, Safety, and… (NCT07570654) | Bored Studies